May 21 (Reuters) - Drug developer Vectura Group Plc reported a 20 percent rise in full-year revenue as it benefitedfrom higher royalty payments for drugs it has licensed.
The company, which develops and markets drugs for asthma andchronic obstructive pulmonary disease, said pretax loss narrowedto 4.8 million pounds from 10.4 million pounds a year earlier.
Revenue rose to 36.5 million pounds in the year ended March31 from 30.5 million pounds a year earlier. (Reporting by Roshni Menon; Editing by Gopakumar Warrier)